Pubblicazioni

1: Oliva P, Suresh RR, Pasquini S, Salmaso V, Will EJ, Tosh DK, Gao ZG, Liu N,

Gavrilova O, Vincenzi F, Varani K, Jacobson KA. 2-Amino-5-arylethynyl-

thiophen-3-yl-(phenyl)methanones as A1 Adenosine Receptor Positive

Allosteric Modulators. ACS Med Chem Lett. 2023 Nov 13;14(12):1640-1646. doi:

10.1021/acsmedchemlett.3c00315. PMID: 38116442; PMCID: PMC10726435.

2: Fernandez M, Nigro M, Travagli A, Pasquini S, Vincenzi F, Varani K, Borea PA,

Merighi S, Gessi S. Strategies for Drug Delivery into the Brain: A Review on

Adenosine Receptors Modulation for Central Nervous System Diseases Therapy.

Pharmaceutics. 2023 Oct 10;15(10):2441. doi: 10.3390/pharmaceutics15102441.

PMID: 37896201; PMCID: PMC10610137.

3: Vincenzi F, Pasquini S, Contri C, Cappello M, Nigro M, Travagli A, Merighi S,

Gessi S, Borea PA, Varani K. Pharmacology of Adenosine Receptors: Recent

Advancements. Biomolecules. 2023 Sep 14;13(9):1387. doi: 10.3390/biom13091387.

PMID: 37759787; PMCID: PMC10527030.

4: Papa A, Cursaro I, Pozzetti L, Contri C, Cappello M, Pasquini S, Carullo G,

Ramunno A, Gemma S, Varani K, Butini S, Campiani G, Vincenzi F. Pioneering

first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective

agents. Arch Pharm (Weinheim). 2023 Dec;356(12):e2300410. doi:

10.1002/ardp.202300410. Epub 2023 Sep 26. PMID: 37750286.

5: Merighi S, Travagli A, Nigro M, Pasquini S, Cappello M, Contri C, Varani K,

Vincenzi F, Borea PA, Gessi S. Caffeine for Prevention of Alzheimer's Disease:

Is the A2A Adenosine Receptor Its Target? Biomolecules. 2023 Jun

8;13(6):967. doi: 10.3390/biom13060967. PMID: 37371547; PMCID: PMC10296091.

6: Corli G, Tirri M, Bilel S, Arfè R, Coccini T, Roda E, Marchetti B, VincenziF, Zauli G, Borea PA, Locatelli CA, Varani K, Marti M. MAM-2201 acuteadministration impairs motor, sensorimotor, prepulse inhibition, and memoryfunctions in mice: a comparison with its analogue AM-2201. Psychopharmacology(Berl). 2023 Jul;240(7):1435-1452. doi: 10.1007/s00213-023-06378-8. Epub 2023May 26. PMID: 37233813; PMCID: PMC10272271.

7: Gianferrara T, Pavan M, Bassani D, Vincenzi F, Pasquini S, Bolcato G, VaraniK, Spalluto G, Federico S, Moro S. Are Two Riboses Better Than One? The Case ofthe Recognition and Activation of Adenosine Receptors. ChemMedChem. 2023 Jul17;18(14):e202300109. doi: 10.1002/cmdc.202300109. Epub 2023 May 10. PMID:37114338.
8: Cammarota M, Ferlenghi F, Vacondio F, Vincenzi F, Varani K, Bedini A, RivaraS, Mor M, Boscia F. Combined targeting of fatty acid amide hydrolase andmelatonin receptors promotes neuroprotection and stimulates inflammationresolution in rats. Br J Pharmacol. 2023 May;180(10):1316-1338. doi:10.1111/bph.16014. Epub 2023 Jan 6. PMID: 36526591.
9: Papa A, Pasquini S, Galvani F, Cammarota M, Contri C, Carullo G, Gemma S,Ramunno A, Lamponi S, Gorelli B, Saponara S, Varani K, Mor M, Campiani G, BosciaF, Vincenzi F, Lodola A, Butini S. Development of potent and selective FAAHinhibitors with improved drug-like properties as potential tools to treatneuroinflammatory conditions. Eur J Med Chem. 2023 Jan 15;246:114952. doi:10.1016/j.ejmech.2022.114952. Epub 2022 Nov 25. PMID: 36462439.
10: Pasquini S, Contri C, Cappello M, Borea PA, Varani K, Vincenzi F. Update onthe recent development of allosteric modulators for adenosine receptors andtheir therapeutic applications. Front Pharmacol. 2022 Oct 5;13:1030895. doi:10.3389/fphar.2022.1030895. PMID: 36278183; PMCID: PMC9581118.
11: Carullo G, Bottoni L, Pasquini S, Papa A, Contri C, Brogi S, Calderone V,Orlandini M, Gemma S, Varani K, Butini S, Galvagni F, Vincenzi F, Campiani G.Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promotingβ-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells.ChemMedChem. 2022 Dec 16;17(24):e202200456. doi: 10.1002/cmdc.202200456. Epub2022 Oct 27. PMID: 36194001.
12: Mari M, Elisi GM, Bedini A, Lucarini S, Retini M, Lucini V, Scaglione F,Vincenzi F, Varani K, Castelli R, Mor M, Rivara S, Spadoni G. 2-Arylmelatoninanalogues: Probing the 2-phenyl binding pocket of melatonin MT1 andMT2 receptors. Eur J Med Chem. 2022 Dec 5;243:114762. doi:10.1016/j.ejmech.2022.114762. Epub 2022 Sep 14. PMID: 36150258.
13: Tirri M, Arfè R, Bilel S, Corli G, Marchetti B, Fantinati A, Vincenzi F, De-Giorgio F, Camuto C, Mazzarino M, Barbieri M, Gaudio RM, Varani K, Borea PA,Botrè F, Marti M. In Vivo Bio-Activation of JWH-175 to JWH-018: Pharmacodynamicand Pharmacokinetic Studies in Mice. Int J Mol Sci. 2022 Jul 21;23(14):8030.doi: 10.3390/ijms23148030. PMID: 35887377; PMCID: PMC9318133.
14: Merighi S, Borea PA, Varani K, Vincenzi F, Travagli A, Nigro M, Pasquini S,Suresh RR, Kim SW, Volkow ND, Jacobson KA, Gessi S. Pathophysiological Role andMedicinal Chemistry of A2A Adenosine Receptor Antagonists inAlzheimer's Disease. Molecules. 2022 Apr 21;27(9):2680. doi:10.3390/molecules27092680. PMID: 35566035; PMCID: PMC9102440.
15: Merighi S, Nigro M, Travagli A, Pasquini S, Borea PA, Varani K, Vincenzi F,Gessi S. A2A Adenosine Receptor: A Possible Therapeutic Target forAlzheimer's Disease by Regulating NLRP3 Inflammasome Activity? Int J Mol Sci.2022 May 2;23(9):5056. doi: 10.3390/ijms23095056. PMID: 35563447; PMCID:PMC9101264.
16: Federico S, Khan T, Fontana A, Brogi S, Benedetti R, Sarno F, Carullo G,Pezzotta A, Saraswati AP, Passaro E, Pozzetti L, Papa A, Relitti N, Gemma S,Butini S, Pistocchi A, Ramunno A, Vincenzi F, Varani K, Tatangelo V, Patrussi L,Baldari CT, Saponara S, Gorelli B, Lamponi S, Valoti M, Saccoccia F, GiannaccariM, Ruberti G, Herp D, Jung M, Altucci L, Campiani G. Azetidin-2-one-based smallmolecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism ofaction and impact of dual inhibition profile on cell viability. Eur J Med Chem.2022 Aug 5;238:114409. doi: 10.1016/j.ejmech.2022.114409. Epub 2022 May 1. PMID:35551034.
17: Catarzi D, Varano F, Vigiani E, Calenda S, Melani F, Varani K, Vincenzi F,Pasquini S, Mennini N, Nerli G, Dal Ben D, Volpini R, Colotta V. 4-HeteroarylSubstituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: NovelInsights on Structure-Activity Relationships and Perspectives. Pharmaceuticals(Basel). 2022 Apr 14;15(4):478. doi: 10.3390/ph15040478. PMID: 35455475; PMCID:PMC9024521.
18: Domenicale C, Mercatelli D, Albanese F, Novello S, Vincenzi F, Varani K,Morari M. Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-SynucleinLevels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice. Biomedicines. 2022 Apr12;10(4):881. doi: 10.3390/biomedicines10040881. PMID: 35453631; PMCID:PMC9027615.
19: Pasquini S, Contri C, Merighi S, Gessi S, Borea PA, Varani K, Vincenzi F.Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators ofNeurotransmission and Potential Therapeutic Targets. Int J Mol Sci. 2022 Jan22;23(3):1219. doi: 10.3390/ijms23031219. PMID: 35163142; PMCID: PMC8835915.
20: Papa A, Pasquini S, Contri C, Gemma S, Campiani G, Butini S, Varani K,Vincenzi F. Polypharmacological Approaches for CNS Diseases: Focus onEndocannabinoid Degradation Inhibition. Cells. 2022 Jan 29;11(3):471. doi:10.3390/cells11030471. PMID: 35159280; PMCID: PMC8834510.
21: Merighi S, Borea PA, Varani K, Vincenzi F, Jacobson KA, Gessi S.A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.Curr Med Chem. 2022;29(24):4138-4151. doi: 10.2174/0929867328666211129122550.PMID: 34844537; PMCID: PMC9148371.
22: Vincenzi F, Rotondo JC, Pasquini S, Di Virgilio F, Varani K, Tognon M.A3 Adenosine and P2X7 Purinergic Receptors as New Targets for anInnovative Pharmacological Therapy of Malignant Pleural Mesothelioma. FrontOncol. 2021 Oct 1;11:679285. doi: 10.3389/fonc.2021.679285. PMID: 34660262;PMCID: PMC8518529.
23: Gessi S, Poloni TE, Negro G, Varani K, Pasquini S, Vincenzi F, Borea PA,Merighi S. A2A Adenosine Receptor as a Potential Biomarker and aPossible Therapeutic Target in Alzheimer's Disease. Cells. 2021 Sep7;10(9):2344. doi: 10.3390/cells10092344. PMID: 34571993; PMCID: PMC8469578.
24: Capone F, Salati S, Vincenzi F, Liberti M, Aicardi G, Apollonio F, Varani K,Cadossi R, Di Lazzaro V. Pulsed Electromagnetic Fields: A Novel AttractiveTherapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia.Neuromodulation. 2022 Dec;25(8):1240-1247. doi: 10.1111/ner.13489. Epub 2022 Feb2. PMID: 34480781.
25: Pasquini S, Contri C, Borea PA, Vincenzi F, Varani K. Adenosine andInflammation: Here, There and Everywhere. Int J Mol Sci. 2021 Jul19;22(14):7685. doi: 10.3390/ijms22147685. PMID: 34299305; PMCID: PMC8304851.
26: Viaro R, Longo F, Vincenzi F, Varani K, Morari M. l-DOPA promotes striataldopamine release through D1 receptors and reversal of dopamine transporter.Brain Res. 2021 Oct 1;1768:147583. doi: 10.1016/j.brainres.2021.147583. Epub2021 Jul 17. PMID: 34284020.
27: Merighi S, Poloni TE, Pelloni L, Pasquini S, Varani K, Vincenzi F, Borea PA,Gessi S. An Open Question: Is the A2A Adenosine Receptor a NovelTarget for Alzheimer's Disease Treatment? Front Pharmacol. 2021 Mar22;12:652455. doi: 10.3389/fphar.2021.652455. PMID: 33828485; PMCID: PMC8019913.
28: Merighi S, Battistello E, Casetta I, Gragnaniello D, Poloni TE, Medici V,Cirrincione A, Varani K, Vincenzi F, Borea PA, Gessi S. Upregulation of CorticalA2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer'sDisease. J Alzheimers Dis. 2021;80(3):1105-1117. doi: 10.3233/JAD-201437. PMID:33646165.
29: Ferrante A, Boussadia Z, Borreca A, Mallozzi C, Pedini G, Pacini L, PezzolaA, Armida M, Vincenzi F, Varani K, Bagni C, Popoli P, Martire A. AdenosineA2A receptor inhibition reduces synaptic and cognitive hippocampalalterations in Fmr1 KO mice. Transl Psychiatry. 2021 Feb 5;11(1):112. doi:10.1038/s41398-021-01238-5. PMID: 33547274; PMCID: PMC7864914.
30: Varani K, Vincenzi F, Pasquini S, Blo I, Salati S, Cadossi M, De Mattei M.Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis:Signaling Pathways and Therapeutic Implications. Int J Mol Sci. 2021 Jan15;22(2):809. doi: 10.3390/ijms22020809. PMID: 33467447; PMCID: PMC7830993.
31: Vincenzi F, Pasquini S, Battistello E, Merighi S, Gessi S, Borea PA, VaraniK. A1 Adenosine Receptor Partial Agonists and Allosteric Modulators:Advancing Toward the Clinic? Front Pharmacol. 2020 Dec 9;11:625134. doi:10.3389/fphar.2020.625134. PMID: 33362567; PMCID: PMC7756085.
32: Vincenzi F, Pasquini S, Borea PA, Varani K. Targeting Adenosine Receptors: APotential Pharmacological Avenue for Acute and Chronic Pain. Int J Mol Sci. 2020Nov 18;21(22):8710. doi: 10.3390/ijms21228710. PMID: 33218074; PMCID:PMC7698931.
33: Vincenzi F, Pasquini S, Setti S, Salati S, Cadossi R, Borea PA, Varani K.Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in1321N1 Human Astrocytes Protecting Neuron-Like SH-SY5Y Cells from Oxygen-GlucoseDeprivation. Int J Mol Sci. 2020 Oct 28;21(21):8053. doi: 10.3390/ijms21218053.PMID: 33126773; PMCID: PMC7663527.
34: Colombini A, Perucca Orfei C, Vincenzi F, De Luca P, Ragni E, Viganò M,Setti S, Varani K, de Girolamo L. A2A adenosine receptors are involved in thereparative response of tendon cells to pulsed electromagnetic fields. PLoS One.2020 Sep 30;15(9):e0239807. doi: 10.1371/journal.pone.0239807. PMID: 32998161;PMCID: PMC7527253.
35: Varano F, Catarzi D, Vigiani E, Vincenzi F, Pasquini S, Varani K, Colotta V.Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidineDerivatives as New Potent and Selective Adenosine A2A ReceptorInverse Agonists. Pharmaceuticals (Basel). 2020 Jul 24;13(8):161. doi:10.3390/ph13080161. PMID: 32722122; PMCID: PMC7465344.
36: Navarro G, Varani K, Lillo A, Vincenzi F, Rivas-Santisteban R, Raïch I,Reyes-Resina I, Ferreiro-Vera C, Borea PA, Sánchez de Medina V, Nadal X, FrancoR. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoidsacting on cannabinoid CB1, CB2 andCB1/CB2 heteromer receptors. Pharmacol Res. 2020Sep;159:104940. doi: 10.1016/j.phrs.2020.104940. Epub 2020 May 26. PMID:32470563.
37: Vincenzi F, Pasquini S, Gessi S, Merighi S, Romagnoli R, Borea PA, Varani K.The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12Cells Can Be Shifted towards a Neuroprotective Role through A1ARPositive Allosteric Modulation. Cells. 2020 May 18;9(5):1242. doi:10.3390/cells9051242. PMID: 32443448; PMCID: PMC7290574.
38: Pasquini S, Vincenzi F, Casetta I, Laudisi M, Merighi S, Gessi S, Borea PA,Varani K. Adenosinergic System Involvement in Ischemic Stroke Patients'Lymphocytes. Cells. 2020 Apr 25;9(5):1072. doi: 10.3390/cells9051072. PMID:32344922; PMCID: PMC7290971.
39: Varano F, Catarzi D, Vincenzi F, Pasquini S, Pelletier J, Lopes RangelFietto J, Espindola Gelsleichter N, Sarlandie M, Guilbaud A, Sévigny J, VaraniK, Colotta V. Structural investigation on thiazolo[5,4-d]pyrimidines to obtaindual-acting blockers of CD73 and adenosine A2A receptor as potentialantitumor agents. Bioorg Med Chem Lett. 2020 May 1;30(9):127067. doi:10.1016/j.bmcl.2020.127067. Epub 2020 Feb 29. PMID: 32165041.
40: Catarzi D, Varano F, Varani K, Vincenzi F, Pasquini S, Dal Ben D, Volpini R,Colotta V. Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Rangingfrom Pan Ligands to Combined A1/A2B Partial Agonists.Pharmaceuticals (Basel). 2019 Oct 22;12(4):159. doi: 10.3390/ph12040159. PMID:31652622; PMCID: PMC6958422.
41: Merighi S, Gessi S, Bencivenni S, Battistello E, Vincenzi F, Setti S,Cadossi M, Borea PA, Cadossi R, Varani K. Signaling pathways involved in anti-inflammatory effects of Pulsed Electromagnetic Field in microglial cells.Cytokine. 2020 Jan;125:154777. doi: 10.1016/j.cyto.2019.154777. Epub 2019 Aug 7.PMID: 31400640.
42: Betti M, Catarzi D, Varano F, Falsini M, Varani K, Vincenzi F, Pasquini S,di Cesare Mannelli L, Ghelardini C, Lucarini E, Dal Ben D, Spinaci A, BartolucciG, Menicatti M, Colotta V. Modifications on the Amino-3,5-dicyanopyridine CoreTo Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity.J Med Chem. 2019 Aug 8;62(15):6894-6912. doi: 10.1021/acs.jmedchem.9b00106. Epub2019 Jul 26. PMID: 31306001.
43: Merighi S, Battistello E, Giacomelli L, Varani K, Vincenzi F, Borea PA,Gessi S. Targeting A3 and A2A adenosine receptors in the fight against cancer.Expert Opin Ther Targets. 2019 Aug;23(8):669-678. doi:10.1080/14728222.2019.1630380. Epub 2019 Jun 12. PMID: 31189400.
44: Gessi S, Merighi S, Bencivenni S, Battistello E, Vincenzi F, Setti S,Cadossi M, Borea PA, Cadossi R, Varani K. Pulsed electromagnetic field andrelief of hypoxia-induced neuronal cell death: The signaling pathway. J CellPhysiol. 2019 Sep;234(9):15089-15097. doi: 10.1002/jcp.28149. Epub 2019 Jan 17.PMID: 30656694.
45: Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-SantistebanR, Sánchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, CanelaEI, Borea PA, Nadal X, Franco R. Cannabigerol Action at CannabinoidCB1 and CB2 Receptors and at CB1-CB2Heteroreceptor Complexes. Front Pharmacol. 2018 Jun 21;9:632. doi:10.3389/fphar.2018.00632. PMID: 29977202; PMCID: PMC6021502.
46: Varano F, Catarzi D, Vincenzi F, Falsini M, Pasquini S, Borea PA, Colotta V,Varani K. Structure-activity relationship studies and pharmacologicalcharacterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivativesas inverse agonists at human A2A adenosine receptor. Eur J Med Chem.2018 Jul 15;155:552-561. doi: 10.1016/j.ejmech.2018.06.020. Epub 2018 Jun 9.PMID: 29909340.
47: Varano F, Catarzi D, Falsini M, Vincenzi F, Pasquini S, Varani K, Colotta V.Identification of novel thiazolo[5,4-d]pyrimidine derivatives as humanA1 and A2A adenosine receptor antagonists/inverseagonists. Bioorg Med Chem. 2018 Jul 23;26(12):3688-3695. doi:10.1016/j.bmc.2018.05.048. Epub 2018 May 31. PMID: 29880250.
48: Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology ofAdenosine Receptors: The State of the Art. Physiol Rev. 2018 Jul1;98(3):1591-1625. doi: 10.1152/physrev.00049.2017. PMID: 29848236.
49: Catarzi D, Varano F, Falsini M, Varani K, Vincenzi F, Pasquini S, Dal Ben D,Colotta V. Development of novel pyridazinone-based adenosine receptor ligands.Bioorg Med Chem Lett. 2018 May 15;28(9):1484-1489. doi:10.1016/j.bmcl.2018.03.086. Epub 2018 Mar 30. PMID: 29627261.
50: Betti M, Catarzi D, Varano F, Falsini M, Varani K, Vincenzi F, Dal Ben D,Lambertucci C, Colotta V. The aminopyridine-3,5-dicarbonitrile core for thedesign of new non-nucleoside-like agonists of the human adenosine A2Breceptor. Eur J Med Chem. 2018 Apr 25;150:127-139. doi:10.1016/j.ejmech.2018.02.081. Epub 2018 Mar 6. PMID: 29525433.
51: Gessi S, Bencivenni S, Battistello E, Vincenzi F, Colotta V, Catarzi D,Varano F, Merighi S, Borea PA, Varani K. Inhibition of A2A AdenosineReceptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455.Front Pharmacol. 2017 Dec 1;8:888. doi: 10.3389/fphar.2017.00888. PMID:29249971; PMCID: PMC5716981.
52: Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F,Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, Navarro G, BoreaPA, Franco R. Binding and Signaling Studies Disclose a Potential Allosteric Sitefor Cannabidiol in Cannabinoid CB2 Receptors. Front Pharmacol. 2017Oct 23;8:744. doi: 10.3389/fphar.2017.00744. PMID: 29109685; PMCID: PMC5660261.
53: Ossato A, Uccelli L, Bilel S, Canazza I, Di Domenico G, Pasquali M, PupilloG, De Luca MA, Boschi A, Vincenzi F, Rimondo C, Beggiato S, Ferraro L, Varani K,Borea PA, Serpelloni G, De-Giorgio F, Marti M. Psychostimulant Effect of theSynthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and DopamineTransporter Scan Imaging Studies in Mice. Front Psychiatry. 2017 Aug 4;8:130.doi: 10.3389/fpsyt.2017.00130. PMID: 28824464; PMCID: PMC5543288.
54: Tschon M, Veronesi F, Contartese D, Sartori M, Martini L, Vincenzi F, RavaniA, Varani K, Fini M. Effects of pulsed electromagnetic fields and platelet richplasma in preventing osteoclastogenesis in an in vitro model of osteolysis. JCell Physiol. 2018 Mar;233(3):2645-2656. doi: 10.1002/jcp.26143. Epub 2017 Sep4. PMID: 28786478.
55: Varani K, Vincenzi F, Merighi S, Gessi S, Borea PA. Biochemical andPharmacological Role of A1 Adenosine Receptors and Their Modulationas Novel Therapeutic Strategy. Adv Exp Med Biol. 2017;1051:193-232. doi:10.1007/5584_2017_61. PMID: 28676923.
56: Canazza I, Ossato A, Vincenzi F, Gregori A, Di Rosa F, Nigro F, Rimessi A,Pinton P, Varani K, Borea PA, Marti M. Pharmaco-toxicological effects of thenovel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. HumPsychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2601. Epub 2017 Jun 9. PMID:28597570.
57: Ravani A, Vincenzi F, Bortoluzzi A, Padovan M, Pasquini S, Gessi S, MerighiS, Borea PA, Govoni M, Varani K. Role and Function of A2A and A₃Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritisand Rheumatoid Arthritis. Int J Mol Sci. 2017 Mar 24;18(4):697. doi:10.3390/ijms18040697. PMID: 28338619; PMCID: PMC5412283.
58: Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I,Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E,Morari M. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol Commun. 2017 Mar14;5(1):22. doi: 10.1186/s40478-017-0426-8. PMID: 28292328; PMCID: PMC5351259.
59: Varani K, Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Setti S,Cadossi M, Borea PA, Cadossi R. Adenosine Receptors as a Biological Pathway forthe Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy PulsedElectromagnetic Fields. Mediators Inflamm. 2017;2017:2740963. doi:10.1155/2017/2740963. Epub 2017 Feb 1. PMID: 28255202; PMCID: PMC5309410.
60: Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pathologicaloverproduction: the bad side of adenosine. Br J Pharmacol. 2017Jul;174(13):1945-1960. doi: 10.1111/bph.13763. Epub 2017 Mar 31. PMID: 28252203;PMCID: PMC6398520.
61: Squarcialupi L, Betti M, Catarzi D, Varano F, Falsini M, Ravani A, PasquiniS, Vincenzi F, Salmaso V, Sturlese M, Varani K, Moro S, Colotta V. The role of5-arylalkylamino- and 5-piperazino- moieties on the7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 andA2A receptor affinity and selectivity profiles. J Enzyme Inhib MedChem. 2017 Dec;32(1):248-263. doi: 10.1080/14756366.2016.1247060. PMID:28114825; PMCID: PMC6009979.
62: Vincenzi F, Borea PA, Varani K. Anxiolytic properties of A1 adenosinereceptor PAMs. Oncotarget. 2017 Jan 31;8(5):7216-7217. doi:10.18632/oncotarget.13802. PMID: 28055953; PMCID: PMC5352310.
63: Merighi S, Bencivenni S, Vincenzi F, Varani K, Borea PA, Gessi S.A2B adenosine receptors stimulate IL-6 production in primary murinemicroglia through p38 MAPK kinase pathway. Pharmacol Res. 2017 Mar;117:9-19.doi: 10.1016/j.phrs.2016.11.024. Epub 2016 Dec 11. PMID: 27974241.
64: Varano F, Catarzi D, Vincenzi F, Betti M, Falsini M, Ravani A, Borea PA,Colotta V, Varani K. Design, Synthesis, and Pharmacological Characterization of2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New HighlyPotent A2A Adenosine Receptor Inverse Agonists with AntinociceptiveActivity. J Med Chem. 2016 Dec 8;59(23):10564-10576. doi:10.1021/acs.jmedchem.6b01068. Epub 2016 Nov 29. PMID: 27933962.
65: Sartori M, Vincenzi F, Ravani A, Cepollaro S, Martini L, Varani K, Fini M,Tschon M. RAW 264.7 co-cultured with ultra-high molecular weight polyethyleneparticles spontaneously differentiate into osteoclasts: an in vitro model ofperiprosthetic osteolysis. J Biomed Mater Res A. 2017 Feb;105(2):510-520. doi:10.1002/jbm.a.35912. Epub 2016 Nov 3. PMID: 27667508.
66: Poli D, Falsini M, Varano F, Betti M, Varani K, Vincenzi F, Pugliese AM,Pedata F, Dal Ben D, Thomas A, Palchetti I, Bettazzi F, Catarzi D, Colotta V.Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptorantagonists: Structural exploration to target the A3 andA2A subtypes. Eur J Med Chem. 2017 Jan 5;125:611-628. doi:10.1016/j.ejmech.2016.09.076. Epub 2016 Sep 26. PMID: 27721147.
67: Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Romagnoli R, BaraldiPG, Borea PA, Varani K. Positive allosteric modulation of A1adenosine receptors as a novel and promising therapeutic strategy for anxiety.Neuropharmacology. 2016 Dec;111:283-292. doi: 10.1016/j.neuropharm.2016.09.015.Epub 2016 Sep 14. PMID: 27639989.
68: Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Setti S, Cadossi R,Borea PA, Varani K. Pulsed Electromagnetic Field Exposure Reduces Hypoxia andInflammation Damage in Neuron-Like and Microglial Cells. J Cell Physiol. 2017May;232(5):1200-1208. doi: 10.1002/jcp.25606. Epub 2016 Oct 7. PMID: 27639248.
69: Bortoluzzi A, Vincenzi F, Govoni M, Padovan M, Ravani A, Borea PA, Varani K.A2A adenosine receptor upregulation correlates with disease activity in patientswith systemic lupus erythematosus. Arthritis Res Ther. 2016 Aug 26;18(1):192.doi: 10.1186/s13075-016-1089-8. PMID: 27566294; PMCID: PMC5002091.
70: Canazza I, Ossato A, Trapella C, Fantinati A, De Luca MA, Margiani G,Vincenzi F, Rimondo C, Di Rosa F, Gregori A, Varani K, Borea PA, Serpelloni G,Marti M. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on"tetrad", sensorimotor, neurological and neurochemical responses in mice. Invitro and in vivo pharmacological studies. Psychopharmacology (Berl). 2016Oct;233(21-22):3685-3709. doi: 10.1007/s00213-016-4402-y. Epub 2016 Aug 15.PMID: 27527584.
71: Squarcialupi L, Falsini M, Catarzi D, Varano F, Betti M, Varani K, VincenziF, Dal Ben D, Lambertucci C, Volpini R, Colotta V. Exploring the 2- and5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1and A2A adenosine receptors. Bioorg Med Chem. 2016 Jun 15;24(12):2794-808. doi:10.1016/j.bmc.2016.04.048. Epub 2016 Apr 23. PMID: 27161878.
72: Aghazadeh Tabrizi M, Baraldi PG, Ruggiero E, Saponaro G, Baraldi S, Poli G,Tuccinardi T, Ravani A, Vincenzi F, Borea PA, Varani K. Synthesis and structureactivity relationship investigation of triazolo[1,5-a]pyrimidines as CB2cannabinoid receptor inverse agonists. Eur J Med Chem. 2016 May 4;113:11-27.doi: 10.1016/j.ejmech.2016.02.032. Epub 2016 Feb 16. PMID: 26922225.
73: Varani K, Vincenzi F, Targa M, Ravani A, Bastia E, Storoni L, Brambilla S,Almirante N, Impagnatiello F. Repeated Dosing with NCX1404, a Nitric Oxide-Donating Pregabalin, Re-establishes Normal Nociceptive Responses in Mice withStreptozotocin-Induced Painful Diabetic Neuropathy. J Pharmacol Exp Ther. 2016May;357(2):240-7. doi: 10.1124/jpet.115.230193. Epub 2016 Feb 23. PMID:26907623.
74: Ossato A, Canazza I, Trapella C, Vincenzi F, De Luca MA, Rimondo C, VaraniK, Borea PA, Serpelloni G, Marti M. Effect of JWH-250, JWH-073 and theirinteraction on "tetrad", sensorimotor, neurological and neurochemical responsesin mice. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jun 3;67:31-50. doi:10.1016/j.pnpbp.2016.01.007. Epub 2016 Jan 15. PMID: 26780169.
75: Squarcialupi L, Catarzi D, Varano F, Betti M, Falsini M, Vincenzi F, RavaniA, Ciancetta A, Varani K, Moro S, Colotta V. Structural refinement ofpyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selectiveantagonists for the human A3 adenosine receptor. Eur J Med Chem. 2016 Jan27;108:117-133. doi: 10.1016/j.ejmech.2015.11.015. Epub 2015 Nov 17. PMID:26638043.
76: Romagnoli R, Baraldi PG, Lopez-Cara C, Cruz-Lopez O, Moorman AR, Massink A,IJzerman AP, Vincenzi F, Borea PA, Varani K. Synthesis and biological evaluationof a new series of 2-amino-3-aroyl thiophene derivatives as agonist allostericmodulators of the A1 adenosine receptor. A position-dependent effect study. EurJ Med Chem. 2015 Aug 28;101:185-204. doi: 10.1016/j.ejmech.2015.06.041. Epub2015 Jun 24. PMID: 26141910.
77: Baraldi PG, Baraldi S, Saponaro G, Aghazadeh Tabrizi M, Romagnoli R,Ruggiero E, Vincenzi F, Borea PA, Varani K. One-pot reaction to obtainN,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidinescaffold as human A3 adenosine receptor antagonists. J Med Chem. 2015 Jul9;58(13):5355-60. doi: 10.1021/acs.jmedchem.5b00551. Epub 2015 Jun 17. PMID:26046697.
78: Varano F, Catarzi D, Squarcialupi L, Betti M, Vincenzi F, Ravani A, VaraniK, Dal Ben D, Thomas A, Volpini R, Colotta V. Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptorantagonists. Synthesis, molecular modeling studies and pharmacologicalevaluation. Eur J Med Chem. 2015;96:105-21. doi: 10.1016/j.ejmech.2015.04.010.Epub 2015 Apr 4. PMID: 25874336.
79: Preti D, Baraldi PG, Saponaro G, Romagnoli R, Aghazadeh Tabrizi M, BaraldiS, Cosconati S, Bruno A, Novellino E, Vincenzi F, Ravani A, Borea PA, Varani K.Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent andselective agonists of the A2A adenosine receptor. J Med Chem. 2015 Apr9;58(7):3253-67. doi: 10.1021/acs.jmedchem.5b00215. Epub 2015 Mar 25. PMID:25780876.
80: Vigolo A, Ossato A, Trapella C, Vincenzi F, Rimondo C, Seri C, Varani K,Serpelloni G, Marti M. Novel halogenated derivates of JWH-018: Behavioral andbinding studies in mice. Neuropharmacology. 2015 Aug;95:68-82. doi:10.1016/j.neuropharm.2015.02.008. Epub 2015 Mar 11. PMID: 25769232.
81: Borea PA, Varani K, Vincenzi F, Baraldi PG, Tabrizi MA, Merighi S, Gessi S.The A3 adenosine receptor: history and perspectives. Pharmacol Rev.2015;67(1):74-102. doi: 10.1124/pr.113.008540. PMID: 25387804.
82: Romagnoli R, Baraldi PG, IJzerman AP, Massink A, Cruz-Lopez O, Lopez-CaraLC, Saponaro G, Preti D, Aghazadeh Tabrizi M, Baraldi S, Moorman AR, Vincenzi F,Borea PA, Varani K. Synthesis and biological evaluation of novel allostericenhancers of the A1 adenosine receptor based on2-amino-3-(4'-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene. J Med Chem.2014 Sep 25;57(18):7673-86. doi: 10.1021/jm5008853. Epub 2014 Sep 12. PMID:25181013.
83: Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, BeggiatoS, Tebano MT, Popoli P. Expression, pharmacology and functional activity ofadenosine A1 receptors in genetic models of Huntington's disease. Neurobiol Dis.2014 Nov;71:193-204. doi: 10.1016/j.nbd.2014.08.013. Epub 2014 Aug 15. PMID:25132555.
84: Squarcialupi L, Colotta V, Catarzi D, Varano F, Betti M, Varani K, VincenziF, Borea PA, Porta N, Ciancetta A, Moro S.7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigationsat the 5-position to target human A₁ and A(2A) adenosine receptors. Molecularmodeling and pharmacological studies. Eur J Med Chem. 2014 Sep 12;84:614-27.doi: 10.1016/j.ejmech.2014.07.060. Epub 2014 Jul 19. PMID: 25063944.
85: Vincenzi F, Targa M, Romagnoli R, Merighi S, Gessi S, Baraldi PG, Borea PA,Varani K. TRR469, a potent A(1) adenosine receptor allosteric modulator,exhibits anti-nociceptive properties in acute and neuropathic pain models inmice. Neuropharmacology. 2014 Jun;81:6-14. doi:10.1016/j.neuropharm.2014.01.028. Epub 2014 Jan 31. PMID: 24486382.
86: Romagnoli R, Baraldi PG, Carrion MD, Cruz-Lopez O, Cara CL, Saponaro G,Preti D, Tabrizi MA, Baraldi S, Moorman AR, Vincenzi F, Borea PA, Varani K.Synthesis and biological evaluation of novel2-amino-3-aroyl-4-neopentyl-5-substituted thiophene derivatives as allostericenhancers of the A₁ adenosine receptor. Bioorg Med Chem. 2014 Jan1;22(1):148-66. doi: 10.1016/j.bmc.2013.11.043. Epub 2013 Dec 1. PMID: 24332652.
87: Casetta I, Vincenzi F, Bencivelli D, Corciulo C, Gentile M, Granieri E,Borea PA, Varani K. A(2A) adenosine receptors and Parkinson's disease severity.Acta Neurol Scand. 2014 Apr;129(4):276-81. doi: 10.1111/ane.12181. Epub 2013 Aug30. PMID: 24032478.
88: Romagnoli R, Baraldi PG, Carrion MD, Lopez Cara C, Kimatrai Salvador M,Preti D, Aghazadeh Tabrizi M, Moorman AR, Vincenzi F, Borea PA, Varani K.Synthesis and biological effects of novel2-amino-3-(4-chlorobenzoyl)-4-substituted thiophenes as allosteric enhancersof the A1 adenosine receptor. Eur J Med Chem. 2013 Sep;67:409-27. doi:10.1016/j.ejmech.2013.07.002. Epub 2013 Jul 13. PMID: 23911855.
89: Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R,Goldring MB, Borea PA, Varani K. Pulsed electromagnetic fields increased theanti-inflammatory effect of A₂A and A₃ adenosine receptors in human T/C-28a2chondrocytes and hFOB 1.19 osteoblasts. PLoS One. 2013 May 31;8(5):e65561. doi:10.1371/journal.pone.0065561. PMID: 23741498; PMCID: PMC3669296.
90: Aghazadeh Tabrizi M, Baraldi PG, Saponaro G, Moorman AR, Romagnoli R, PretiD, Baraldi S, Ruggiero E, Tintori C, Tuccinardi T, Vincenzi F, Borea PA, VaraniK. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent andselective CB(2) cannabinoid receptor inverse agonists. J Med Chem. 2013 Jun13;56(11):4482-96. doi: 10.1021/jm400182t. Epub 2013 Jun 4. PMID: 23697626.
91: Vincenzi F, Corciulo C, Targa M, Casetta I, Gentile M, Granieri E, Borea PA,Popoli P, Varani K. A2A adenosine receptors are up-regulated in lymphocytes fromamyotrophic lateral sclerosis patients. Amyotroph Lateral Scler FrontotemporalDegener. 2013 Sep;14(5-6):406-13. doi: 10.3109/21678421.2013.793358. Epub 2013May 16. PMID: 23679925.
92: Vincenzi F, Corciulo C, Targa M, Merighi S, Gessi S, Casetta I, Gentile M,Granieri E, Borea PA, Varani K. Multiple sclerosis lymphocytes upregulate A2Aadenosine receptors that are antiinflammatory when stimulated. Eur J Immunol.2013 Aug;43(8):2206-16. doi: 10.1002/eji.201343314. Epub 2013 Jun 3. PMID:23661562.
93: Vincenzi F, Targa M, Corciulo C, Tabrizi MA, Merighi S, Gessi S, Saponaro G,Baraldi PG, Borea PA, Varani K. Antinociceptive effects of the selective CB2agonist MT178 in inflammatory and chronic rodent pain models. Pain. 2013Jun;154(6):864-73. doi: 10.1016/j.pain.2013.02.007. Epub 2013 Feb 26. PMID:23518609.
94: Squarcialupi L, Colotta V, Catarzi D, Varano F, Filacchioni G, Varani K,Corciulo C, Vincenzi F, Borea PA, Ghelardini C, Di Cesare Mannelli L, CiancettaA, Moro S. 2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent andselective human A3 adenosine receptor antagonists. Molecular modeling studiesand pharmacological evaluation. J Med Chem. 2013 Mar 28;56(6):2256-69. doi:10.1021/jm400068e. Epub 2013 Mar 7. PMID: 23427825.
95: Aghazadeh Tabrizi M, Baraldi PG, Saponaro G, Moorman AR, Romagnoli R, PretiD, Baraldi S, Corciulo C, Vincenzi F, Borea PA, Varani K. Design, synthesis, andpharmacological properties of new heteroarylpyridine/heteroarylpyrimidinederivatives as CB(2) cannabinoid receptor partial agonists. J Med Chem. 2013 Feb14;56(3):1098-112. doi: 10.1021/jm301527r. Epub 2013 Feb 1. PMID: 23350768.
96: Fini M, Pagani S, Giavaresi G, De Mattei M, Ongaro A, Varani K, Vincenzi F,Massari L, Cadossi M. Functional tissue engineering in articular cartilagerepair: is there a role for electromagnetic biophysical stimulation? Tissue EngPart B Rev. 2013 Aug;19(4):353-67. doi: 10.1089/ten.TEB.2012.0501. Epub 2013 Mar19. PMID: 23339690.
97: Vincenzi F, Padovan M, Targa M, Corciulo C, Giacuzzo S, Merighi S, Gessi S,Govoni M, Borea PA, Varani K. A(2A) adenosine receptors are differentiallymodulated by pharmacological treatments in rheumatoid arthritis patients andtheir stimulation ameliorates adjuvant-induced arthritis in rats. PLoS One.2013;8(1):e54195. doi: 10.1371/journal.pone.0054195. Epub 2013 Jan 11. PMID:23326596; PMCID: PMC3543361.
98: Catarzi D, Colotta V, Varano F, Poli D, Squarcialupi L, Filacchioni G,Varani K, Vincenzi F, Borea PA, Dal Ben D, Lambertucci C, Cristalli G.Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues asadenosine receptor antagonists: synthesis, structure-affinity relationships andmolecular modeling studies. Bioorg Med Chem. 2013 Jan 1;21(1):283-94. doi:10.1016/j.bmc.2012.10.031. Epub 2012 Oct 29. PMID: 23171656.
99: Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Salvador MK,Preti D, Tabrizi MA, Moorman AR, Vincenzi F, Borea PA, Varani K. Synthesis andbiological evaluation of2-amino-3-(4-chlorobenzoyl)-4-[(4-arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. effect of the 5-modification on allosteric enhancer activity at theA1 adenosine receptor. J Med Chem. 2012 Sep 13;55(17):7719-35. doi:10.1021/jm3007504. Epub 2012 Aug 28. PMID: 22889387.
100: Varani K, Vincenzi F, Targa M, Paradiso B, Parrilli A, Fini M, Lanza G,Borea PA. The stimulation of A(3) adenosine receptors reduces bone-residingbreast cancer in a rat preclinical model. Eur J Cancer. 2013 Jan;49(2):482-91.doi: 10.1016/j.ejca.2012.06.005. Epub 2012 Jul 5. PMID: 22770890.
101: Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R,Borea PA, Varani K. The anti-tumor effect of A3 adenosine receptors ispotentiated by pulsed electromagnetic fields in cultured neural cancer cells.PLoS One. 2012;7(6):e39317. doi: 10.1371/journal.pone.0039317. Epub 2012 Jun 25.PMID: 22761760; PMCID: PMC3382599.
102: Baraldi PG, Saponaro G, Moorman AR, Romagnoli R, Preti D, Baraldi S,Ruggiero E, Varani K, Targa M, Vincenzi F, Borea PA, Aghazadeh Tabrizi M.7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2)cannabinoid receptor ligands: structural investigations around a novel class offull agonists. J Med Chem. 2012 Jul 26;55(14):6608-23. doi: 10.1021/jm300763w.Epub 2012 Jul 11. PMID: 22738271.
103: Dalpiaz A, Cacciari B, Vicentini CB, Bortolotti F, Spalluto G, Federico S,Pavan B, Vincenzi F, Borea PA, Varani K. A novel conjugated agent betweendopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinsonmultitarget approach. Mol Pharm. 2012 Mar 5;9(3):591-604. doi:10.1021/mp200489d. Epub 2012 Feb 9. PMID: 22292533.
104: Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Salvador MK,Preti D, Tabrizi MA, Shryock JC, Moorman AR, Vincenzi F, Varani K, Borea PA.Structure-activity relationships of2-amino-3-aroyl-4-[(4-arylpiperazin-1-yl)methyl]thiophenes. Part 2: Probing theinfluence of diverse substituents at the phenyl of the arylpiperazine moiety onallosteric enhancer activity at the A₁ adenosine receptor. Bioorg Med Chem. 2012Jan 15;20(2):996-1007. doi: 10.1016/j.bmc.2011.11.044. Epub 2011 Dec 1. PMID:22182575.
105: Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, Borea PA. A2Aand A3 adenosine receptor expression in rheumatoid arthritis: upregulation,inverse correlation with disease activity score and suppression of inflammatorycytokine and metalloproteinase release. Arthritis Res Ther. 2011;13(6):R197.doi: 10.1186/ar3527. Epub 2011 Dec 6. PMID: 22146575; PMCID: PMC3334647.
106: Varani K, Vincenzi F, Targa M, Corciulo C, Fini M, Setti S, Cadossi R,Borea PA. Effect of pulsed electromagnetic field exposure on adenosine receptorsin rat brain. Bioelectromagnetics. 2012 May;33(4):279-87. doi:10.1002/bem.20704. Epub 2011 Oct 19. PMID: 22012856.
107: Ongaro A, Varani K, Masieri FF, Pellati A, Massari L, Cadossi R, VincenziF, Borea PA, Fini M, Caruso A, De Mattei M. Electromagnetic fields (EMFs) andadenosine receptors modulate prostaglandin E(2) and cytokine release in humanosteoarthritic synovial fibroblasts. J Cell Physiol. 2012 Jun;227(6):2461-9.doi: 10.1002/jcp.22981. PMID: 21830213.
108: Lenzi O, Colotta V, Catarzi D, Varano F, Squarcialupi L, Filacchioni G,Varani K, Vincenzi F, Borea PA, Dal Ben D, Lambertucci C, Cristalli G.Synthesis, structure-affinity relationships, and molecular modeling studies ofnovel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.Bioorg Med Chem. 2011 Jun 15;19(12):3757-68. doi: 10.1016/j.bmc.2011.05.001.Epub 2011 May 6. PMID: 21616671.
109: Varani K, Maniero S, Vincenzi F, Targa M, Stefanelli A, Maniscalco P,Martini F, Tognon M, Borea PA. A₃ receptors are overexpressed in pleura frompatients with mesothelioma and reduce cell growth via Akt/nuclear factor-κBpathway. Am J Respir Crit Care Med. 2011 Feb 15;183(4):522-30. doi:10.1164/rccm.201006-0980OC. Epub 2010 Sep 24. PMID: 20870754.
110: Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, Borea PA. The role ofadenosine receptors in rheumatoid arthritis. Autoimmun Rev. 2010 Dec;10(2):61-4.doi: 10.1016/j.autrev.2010.07.019. Epub 2010 Aug 5. PMID: 20691813.
111: Varani K, Vincenzi F, Tosi A, Targa M, Masieri FF, Ongaro A, De Mattei M,Massari L, Borea PA. Expression and functional role of adenosine receptors inregulating inflammatory responses in human synoviocytes. Br J Pharmacol. 2010May;160(1):101-15. doi: 10.1111/j.1476-5381.2010.00667.x. Epub 2010 Mar 19.PMID: 20331607; PMCID: PMC2860211.
112: Varani K, De Mattei M, Vincenzi F, Tosi A, Targa M, Masieri FF, Pellati A,Massari L, Borea PA. P2X(1) and P2X(3) purinergic receptors differentiallymodulate the inflammatory response in human osteoarthritic synovial fibroblasts.Cell Physiol Biochem. 2010;25(2-3):325-36. doi: 10.1159/000276565. Epub 2010 Jan12. PMID: 20110693.
113: Varani K, Caramori G, Vincenzi F, Tosi A, Barczyk A, Contoli M, Casolari P,Triggiani M, Hansel T, Leung E, Maclennan S, Barnes PJ, Chung KF, Adcock I, PapiA, Borea PA. Oxidative/nitrosative stress selectively altered A(2B) adenosinereceptors in chronic obstructive pulmonary disease. FASEB J. 2010Apr;24(4):1192-204. doi: 10.1096/fj.09-139485. Epub 2009 Dec 14. PMID: 20008542.
114: Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, Borea PA.Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoidarthritis patients by treatment with anti-tumor necrosis factor alpha but notmethotrexate. Arthritis Rheum. 2009 Oct;60(10):2880-91. doi: 10.1002/art.24794.PMID: 19790066.
115: Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P,Leung E, MacLennan S, Granieri E, Borea PA. A2A adenosine receptoroverexpression and functionality, as well as TNF-alpha levels, correlate withmotor symptoms in Parkinson's disease. FASEB J. 2010 Feb;24(2):587-98. doi:10.1096/fj.09-141044. Epub 2009 Sep 23. PMID: 19776336.
116: Lenzi O, Colotta V, Catarzi D, Varano F, Poli D, Filacchioni G, Varani K,Vincenzi F, Borea PA, Paoletta S, Morizzo E, Moro S.2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent andselective human A3 adenosine receptor antagonists: new insights into thereceptor-antagonist recognition. J Med Chem. 2009 Dec 10;52(23):7640-52. doi:10.1021/jm900718w. PMID: 19743865.
117: Aguiari G, Varani K, Bogo M, Mangolini A, Vincenzi F, Durante C, Gessi S,Sacchetto V, Catizone L, Harris P, Rizzuto R, Borea PA, Del Senno L. Deficiencyof polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosinereceptors in human renal cells: implications for cAMP-dependent signalling andproliferation of PKD1-mutated cystic cells. Biochim Biophys Acta. 2009Jun;1792(6):531-40. doi: 10.1016/j.bbadis.2009.03.001. Epub 2009 Mar 11. PMID:19285554.
118: Colotta V, Capelli F, Lenzi O, Catarzi D, Varano F, Poli D, Vincenzi F,Varani K, Borea PA, Dal Ben D, Volpini R, Cristalli G, Filacchioni G. Novelpotent and highly selective human A(3) adenosine receptor antagonists belongingto the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysisand pharmacological studies. Bioorg Med Chem. 2009 Jan 1;17(1):401-10. doi:10.1016/j.bmc.2008.10.018. Epub 2008 Oct 11. PMID: 18996701.
119: Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Iaconinoto MA,Preti D, Shryock JC, Moorman AR, Vincenzi F, Varani K, Andrea Borea P. Synthesisand biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted)piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosinereceptor. J Med Chem. 2008 Sep 25;51(18):5875-9. doi: 10.1021/jm800586p. Epub2008 Aug 26. PMID: 18729349.
120: De Mattei M, Varani K, Masieri FF, Pellati A, Ongaro A, Fini M, Cadossi R,Vincenzi F, Borea PA, Caruso A. Adenosine analogs and electromagnetic fieldsinhibit prostaglandin E2 release in bovine synovial fibroblasts. OsteoarthritisCartilage. 2009 Feb;17(2):252-62. doi: 10.1016/j.joca.2008.06.002. Epub 2008 Jul18. PMID: 18640059.
121: Varani K, De Mattei M, Vincenzi F, Tosi A, Gessi S, Merighi S, Pellati A,Masieri F, Ongaro A, Borea PA. Pharmacological characterization of P2X1 and P2X3purinergic receptors in bovine chondrocytes. Osteoarthritis Cartilage. 2008Nov;16(11):1421-9. doi: 10.1016/j.joca.2008.03.016. Epub 2008 Apr 29. PMID:18448363.
122: Varani K, Surprenant A, Vincenzi F, Tosi A, Gessi S, Merighi S, Borea PA.Binding thermodynamic characterization of human P2X1 and P2X3 purinergicreceptors. Biochem Pharmacol. 2008 Mar 1;75(5):1198-208. doi:10.1016/j.bcp.2007.10.034. Epub 2007 Nov 9. PMID: 18076867.
123: Morizzo E, Capelli F, Lenzi O, Catarzi D, Varano F, Filacchioni G, VincenziF, Varani K, Borea PA, Colotta V, Moro S. Scouting human A3 adenosine receptorantagonist binding mode using a molecular simplification approach: fromtriazoloquinoxaline to a pyrimidine skeleton as a key study. J Med Chem. 2007Dec 27;50(26):6596-606. doi: 10.1021/jm070852a. Epub 2007 Nov 30. PMID:18047262.
124: Varani K, De Mattei M, Vincenzi F, Gessi S, Merighi S, Pellati A, Ongaro A,Caruso A, Cadossi R, Borea PA. Characterization of adenosine receptors in bovinechondrocytes and fibroblast-like synoviocytes exposed to low frequency lowenergy pulsed electromagnetic fields. Osteoarthritis Cartilage. 2008Mar;16(3):292-304. doi: 10.1016/j.joca.2007.07.004. Epub 2007 Aug 16. PMID:17698373.
125: Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P,Ghirardi O, Carminati P. ST 1535: a preferential A2A adenosine receptorantagonist. Int J Neuropsychopharmacol. 2006 Oct;9(5):575-84. doi:10.1017/S1461145705006188. Epub 2005 Nov 23. PMID: 16867213.
126: Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, Leung E, MaclennanS, Gessi S, Morello S, Barnes PJ, Ito K, Chung KF, Cavallesco G, Azzena G, PapiA, Borea PA. Alteration of adenosine receptors in patients with chronicobstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Feb15;173(4):398-406. doi: 10.1164/rccm.200506-869OC. Epub 2005 Dec 1. PMID:16322645.
127: Baraldi PG, Pavani MG, Leung E, Moorman AR, Varani K, Vincenzi F, Borea PA,Romagnoli R. Synthesis and biological characterization of [3H](2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone,the first radiolabelled adenosine A1 allosteric enhancer. Bioorg Med Chem Lett.2006 Mar 1;16(5):1402-4. doi: 10.1016/j.bmcl.2005.11.037. PMID: 16321527.
128: Varani K, Gessi S, Merighi S, Vincenzi F, Cattabriga E, Benini A, Klotz KN,Baraldi PG, Tabrizi MA, Lennan SM, Leung E, Borea PA. Pharmacologicalcharacterization of novel adenosine ligands in recombinant and native human A2Breceptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. doi:10.1016/j.bcp.2005.08.018. Epub 2005 Oct 10. PMID: 16219300.
129: Varani K, Portaluppi F, Gessi S, Merighi S, Vincenzi F, Cattabriga E,Dalpiaz A, Bortolotti F, Belardinelli L, Borea PA. Caffeine intake induces analteration in human neutrophil A2A adenosine receptors. Cell Mol Life Sci. 2005Oct;62(19-20):2350-8. doi: 10.1007/s00018-005-5312-z. PMID: 16143823.

Strumenti personali

Pubblicazioni

Università degli Studi di Ferrara

Rettrice: Prof.ssa Laura Ramaciotti